- Home
- STOK vs SANA Comparison
STOK vs SANA Comparison
Compare STOK & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- SANA
- Stock Information
- Founded
- STOK 2014
- SANA 2018
- Country
- STOK United States
- SANA United States
- Employees
- STOK N/A
- SANA N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- STOK Health Care
- SANA Health Care
- Exchange
- STOK Nasdaq
- SANA Nasdaq
- Market Cap
- STOK 517.0M
- SANA 519.8M
- IPO Year
- STOK 2019
- SANA 2021
- Fundamental
- Price
- STOK $9.87
- SANA $2.25
- Analyst Decision
- STOK Strong Buy
- SANA Strong Buy
- Analyst Count
- STOK 5
- SANA 5
- Target Price
- STOK $24.50
- SANA $9.50
- AVG Volume (30 Days)
- STOK 694.7K
- SANA 3.9M
- Earning Date
- STOK 05-13-2025
- SANA 05-08-2025
- Dividend Yield
- STOK N/A
- SANA N/A
- EPS Growth
- STOK N/A
- SANA N/A
- EPS
- STOK 0.88
- SANA N/A
- Revenue
- STOK $190,908,000.00
- SANA N/A
- Revenue This Year
- STOK $44.17
- SANA N/A
- Revenue Next Year
- STOK $20.00
- SANA N/A
- P/E Ratio
- STOK $10.88
- SANA N/A
- Revenue Growth
- STOK 2333.81
- SANA N/A
- 52 Week Low
- STOK $5.35
- SANA $1.26
- 52 Week High
- STOK $17.58
- SANA $8.17
- Technical
- Relative Strength Index (RSI)
- STOK 55.15
- SANA 60.42
- Support Level
- STOK $9.09
- SANA $2.11
- Resistance Level
- STOK $9.83
- SANA $2.35
- Average True Range (ATR)
- STOK 0.61
- SANA 0.20
- MACD
- STOK -0.05
- SANA 0.04
- Stochastic Oscillator
- STOK 51.93
- SANA 81.33
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.